https://seekingalpha.com/article/4765553-daxor-corporation-dxr-q4-2024-earnings-call-transcript [Seeking Alpha]
Daxor Corporation (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: Seeking Alpha
Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024. At this time, all participants are in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] During this call, management will be making forward-looking statements, including statements that address Daxor's expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Daxor's most recently filed annual report on Form N-CSR and subsequent periodic reports filed
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA AnalyzerGlobeNewswire
- Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth SummitGlobeNewswire
- Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25GlobeNewswire
- Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSAGlobeNewswire
DXR
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 11/14/25 - Form 4
- DXR's page on the SEC website